JAK inhibitors in rheumatology
AbstractJanus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action from biologics and are most rapidly uptaken in the rheumatology field. JAK is a protein kinase activated in the cytoplasm by multiple cytokines and hormones involved in inflammatory pathology. The expre...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-07-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/25785826.2023.2172808 |
| _version_ | 1827888738753052672 |
|---|---|
| author | Kunihiro Yamaoka Kenji Oku |
| author_facet | Kunihiro Yamaoka Kenji Oku |
| author_sort | Kunihiro Yamaoka |
| collection | DOAJ |
| description | AbstractJanus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action from biologics and are most rapidly uptaken in the rheumatology field. JAK is a protein kinase activated in the cytoplasm by multiple cytokines and hormones involved in inflammatory pathology. The expression of JAK has been observed in various diseases, indicating the utility of JAK inhibitors in a wide variety of immune-mediated inflammatory diseases. Clinical trials are underway for a number of different rheumatic diseases based on the therapeutic efficacy of JAKis, which is comparable to that of biologics. This article will review the current status of JAKis for rheumatic diseases in terms of efficacy and safety and extend to future clinical applications for rare diseases. |
| first_indexed | 2024-03-12T20:38:05Z |
| format | Article |
| id | doaj.art-53960d179d1d4c92af097e267bd3d919 |
| institution | Directory Open Access Journal |
| issn | 2578-5826 |
| language | English |
| last_indexed | 2024-03-12T20:38:05Z |
| publishDate | 2023-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Immunological Medicine |
| spelling | doaj.art-53960d179d1d4c92af097e267bd3d9192023-08-01T12:02:17ZengTaylor & Francis GroupImmunological Medicine2578-58262023-07-0146314315210.1080/25785826.2023.2172808JAK inhibitors in rheumatologyKunihiro Yamaoka0Kenji Oku1Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, JapanDepartment of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, JapanAbstractJanus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action from biologics and are most rapidly uptaken in the rheumatology field. JAK is a protein kinase activated in the cytoplasm by multiple cytokines and hormones involved in inflammatory pathology. The expression of JAK has been observed in various diseases, indicating the utility of JAK inhibitors in a wide variety of immune-mediated inflammatory diseases. Clinical trials are underway for a number of different rheumatic diseases based on the therapeutic efficacy of JAKis, which is comparable to that of biologics. This article will review the current status of JAKis for rheumatic diseases in terms of efficacy and safety and extend to future clinical applications for rare diseases.https://www.tandfonline.com/doi/10.1080/25785826.2023.2172808Rheumatic diseaseJanus kinase inhibitorsafetyselectivity |
| spellingShingle | Kunihiro Yamaoka Kenji Oku JAK inhibitors in rheumatology Immunological Medicine Rheumatic disease Janus kinase inhibitor safety selectivity |
| title | JAK inhibitors in rheumatology |
| title_full | JAK inhibitors in rheumatology |
| title_fullStr | JAK inhibitors in rheumatology |
| title_full_unstemmed | JAK inhibitors in rheumatology |
| title_short | JAK inhibitors in rheumatology |
| title_sort | jak inhibitors in rheumatology |
| topic | Rheumatic disease Janus kinase inhibitor safety selectivity |
| url | https://www.tandfonline.com/doi/10.1080/25785826.2023.2172808 |
| work_keys_str_mv | AT kunihiroyamaoka jakinhibitorsinrheumatology AT kenjioku jakinhibitorsinrheumatology |